Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 8/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | TTR | P02766 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.77 |
| ▸ | GSK3B | P49841 | 1/20 | 0.77 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.69 |
| ▸ | MMP13 | P45452 | 2/20 | 0.67 |
| ▸ | MMP3 | P08254 | 1/20 | 0.67 |
| ▸ | NAT1 | P18440 | 1/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064978 | 1.00 | PTP4A3 (0.83) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10090211 | 1.00 | PTP4A3 (0.83) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10090224 | 0.91 | PTP4A3 (0.69) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2066112 | 0.91 | PTP4A3 (0.69) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2066109 | 0.91 | PTP4A3 (0.69) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL18102915 | 0.90 | PTP4A3 (0.75) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL883940 | 0.88 | PTP4A3 (0.80) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL883941 | 0.88 | PTP4A3 (0.80) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2066168 | 0.88 | PTP4A3 (1.00) | PTP4A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2066170 | 0.88 | PTP4A3 (1.00) | PTP4A3MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | claimed |
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| WO-2007081091-A1 | RHODANDSE DERIVARIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | PTP4A3 28/4885MEN1 4202/4885KMT2A 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.